Ipamorelin – User Manual & Dosage Protocol Guide

Ipamorelin is a selective growth hormone secretagogue (GHS) studied for its ability to stimulate endogenous growth hormone (GH) release through ghrelin receptor (GHS-R1a) activation in research settings.

It is known for its relatively selective GH-releasing properties compared to earlier GHRP compounds.

Research Applications

• GH pulsatility studies
• IGF-1 modulation research
• Body composition investigations
• Recovery and performance physiology models
• Sleep and endocrine rhythm research

Disclaimer: Ipamorelin is for research and experimental use only in this context. It is not FDA-approved for general therapeutic use.

Lyophilized Powder

Freeze-dried Ipamorelin intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used for subcutaneous research injection after proper reconstitution.

Ipamorelin is studied for its ability to:

• Bind selectively to the ghrelin receptor (GHS-R1a)
• Stimulate pulsatile GH release from the pituitary
• Increase downstream IGF-1 signaling
• Produce minimal stimulation of cortisol and prolactin compared to earlier GHRPs (in research models)

Effects are primarily observed in controlled and investigational protocols.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 200–300 mcg per administration, generally 1–2 times daily. It is often administered in pulse‑timing research models.

Higher‑Range Research

Some studies use 300–500 mcg per administration, typically 1–2 times daily, when evaluating growth hormone response patterns.

Administration Timing

In research settings, timing is frequently aligned with fasting periods or pre‑sleep GH pulse models.

Important

There is no approved dosage outside regulated clinical supervision. The ranges above reflect commonly referenced investigational research patterns only, and any human‑equivalent dosing must be determined by qualified medical or research oversight.

nitiation

A 1–2 week phase used to evaluate growth hormone response and tolerance at the beginning of the study.

Active Study Phase

Typically 8–12 weeks, focused on monitoring IGF‑1 levels and body composition changes.

Extended Model

An optional phase up to 16 weeks for extended endocrine rhythm research.

Rest Period

A 2–4 week interval between cycles to allow the GH-axis to reset.

Note

Cycle duration may vary depending on study endpoints and research objectives.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 5 mg vial + 2 mL → 2.5 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Avoid excessive agitation to preserve peptide stability.

Subcutaneous Injection Model

• Common sites: abdomen, thigh, upper arm
• Clean site prior to administration
• Inject slowly
• Rotate injection sites

Administration scheduling often follows pulse-based GH research designs.

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve product quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

• Research use only
• Not for therapeutic application
• Human safety outside controlled research is not established
• Possible research observations may include:
• Injection-site irritation
• Mild headache
• Temporary flushing
• Water retention (GH-axis related)

Monitoring of IGF-1 and metabolic markers is common in investigational settings.

Maintain sterile technique at all times.

Keep out of reach of children.

Peptide: Ipamorelin
Category: Growth Hormone Secretagogue (GHS)
Delivery Model: Subcutaneous research injection
Typical Investigational Range: 200–500 mcg, 1–2 times daily
Cycle: 8–12 week research models
Storage: Refrigerated after reconstitution